Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.74 |
| ▸ | PDE6C | P51160 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PDE1A | P54750 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19518053 | 0.86 | PDE5A (0.66) | PDE5APDE6CHDAC6HDAC1HDAC2 | |
| SCHEMBL7961020 | 0.85 | PDE5A (1.00) | PDE5APDE6CHDAC6HDAC1HDAC2 | |
| SCHEMBL29393046 | 0.84 | KMT2A (0.62) | PDE5APDE6CKMT2APDE1APDE1B | |
| SCHEMBL22558019 | 0.84 | KMT2A (0.62) | PDE5APDE6CKMT2APDE1APDE1B | |
| SCHEMBL31174348 | 0.84 | PDE5A (0.55) | PDE5APDE6CHDAC6HDAC1HDAC2 | |
| SCHEMBL2032429 | 0.84 | PDE5A (0.78) | PDE5APDE6CHDAC6HDAC1HDAC2 | |
| SCHEMBL18069562 | 0.84 | PDE5A (0.65) | PDE5APDE6CHDAC6HDAC1HDAC2 | |
| SCHEMBL28409645 | 0.83 | KMT2A (0.75) | PDE5APDE6CKMT2APDE1APDE1B | |
| SCHEMBL4369284 | 0.83 | KMT2A (0.62) | PDE5APDE6CKMT2APDE1APDE1B | |
| SCHEMBL29010393 | 0.82 | KMT2A (0.61) | PDE5APDE6CKMT2APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943518-B2 | Inhibitors of phosphodiesterase type 5A for reducing skeletal muscle fatigue, edema, and damage in a patient having muscle fatigue due to increased age or exercise | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160263118-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-09-15 | — | — | US | disclosed |
| US-9387210-B2 | Inhibitors of phosphodiesterase type 5A for treating or preventing muscle disease or the symptoms thereof in a patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140005202-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-01-02 | — | — | US | disclosed |
| US-20110160219-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160219-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 21/4885HDAC6 727/4885 |
| US-20160263118-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 21/4885HDAC6 727/4885 |
| US-20140005202-A1 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 21/4885HDAC6 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.